Ampliphi Biosciences (NYSEAMERICAN:APHB) Stock Passes Below 200 Day Moving Average – Here’s What Happened

Ampliphi Biosciences Corp (NYSEAMERICAN:APHB – Get Free Report) shares crossed below its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $8.35 and traded as low as $6.76. Ampliphi Biosciences shares last traded at $7.06, with a volume of 33,694 shares trading hands.

Ampliphi Biosciences Stock Up 4.0%

The business’s 50 day moving average is $9.36 and its 200-day moving average is $8.35.

About Ampliphi Biosciences

(Get Free Report)

Ampliphi Biosciences, Inc is a clinical‐stage biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on the discovery and development of novel therapies to prevent and treat life‐threatening drug‐resistant infections. The company’s core mission is to address the growing global threat of antibiotic resistance by advancing first‐in‐class and best‐in‐class antibacterial agents through late‐stage clinical trials.

The company’s lead product candidate, exeporfinium chloride (XF-73), is a pioneering topical antibacterial designed for pre‐operative nasal decolonization of Staphylococcus aureus in patients undergoing high‐risk surgical procedures.

Featured Stories

• Five stocks we like better than Ampliphi Biosciences
• Aehr Spikes on New Order, But Has Stock Gotten Ahead of Itself?
• Rackspace’s AI Land Grab: Plugging Into the Next Compute Boom
• Satellogic Is Tiny But Its Revenue Growth Is Hard to Ignore
• Why Kroger’s Pullback Could Be a Gift for Patient Investors